Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles

Journal of Immunotherapy

Volumn 30, Issue 5, 2007, Pages 469-478

  Zhang, Xue Qing ^a   Dahle, Christopher E ^b   Baman, Nicki K ^c   Rich, Nathan ^b   Weiner, George J ^b   Salem, Aliasger K ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c IA United States   (United States)

Author keywords

Biodegradable microparticles; CpG oligonucleotides; Immunotherapy

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; BIODEGRADABILITY; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; IMMUNOGLOBULIN PRODUCTION; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; MATERIAL COATING; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TH1 CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CELL DIFFERENTIATION; CELL LINE; DENDRITIC CELLS; DNA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOGLOBULIN G; LACTIC ACID; MICE; MICE, INBRED C57BL; MICROSPHERES; OVALBUMIN; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; VACCINATION;

EID: 34250839522     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31802fd8c6     Document Type: Article

References (40)

1. Salem AK, Hung CF, Kim TW, et al. Multi-component nanorods for vaccination applications. Nanotechnology. 2005;16:484-487.
2. Sandler AD, Chihara H, Kobayashi G, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003;63:394-399.
3. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA. 1997;94:10833-10837.
4. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol. 1998;16:1025-1031.
5. Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci. 1996;85:1261-1270.
6. Salem AK, Searson PC, Leong KW. Multifunctional nanorods for gene delivery. Nat Materials. 2003;2:668-671.
7. Weiner GJ, Degast GC. Bispecific monoclonal-antibody therapy of B-cell malignancy. Leukemia Lymphoma. 1995;16:199-207.
8. Weiner GJ. CpG DNA in cancer immunotherapy. In: Wagner H, ed. Immunobiology of Bacterial Cpg-DNA. 1st ed. New York: Springer-Verlag; 2000:157-170.
9. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
10. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
11. Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv Polymer Sci. 1990;94:107-141.
12. Mutwiri GK, Nichani AK, Babiuk S, et al. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Controlled Release. 2004;97:1-17.
13. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med. 1998;4:365-368.
14. Wang C, Ge Q, Ting D, et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Materials. 2004;3:190-196.
15. Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5:387-391.
16. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Controlled Release. 2002;85:247-262.
17. Dechy-Cabaret O, Martin-Vaca B, Bourissou D. Controlled ring-opening polymerization of lactide and glycolide. Chemi Rev. 2004;104:6147-6176.
18. Tamber H, Johansen P, Merkle HP, et al. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Delivery Rev. 2005;57:357-376.
19. Jiang WL, Gupta RK, Deshpande MC, et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Delivery Rev. 2005;57:391-410.
20. Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Delivery Rev. 2005;57:475-482.
21. Hedley ML. Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opin Biol Ther. 2003;3:903-910.
22. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136-3143.
23. Joseph A, Louria-Hayon I, Plis-Finarov A, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine. 2002;20:3342-3354.
24. Millan CLB, Weeratna R, Krieg AM, et al. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA. 1998;95:15553-15558.
25. Mullen GED, Giersing BK, Ajose-Popoola O, et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel (R), a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine. 2006;24:2497-2505.
26. Salem AK, Rose F, Oreffo ROC, et al. Porous polymer and cell composites that self-assemble in situ. Adv Materials. 2003;15:210-213.
27. Murakami H, Kawashima Y, Niwa T, et al. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(DL-lactide-co-glycolide) nanoparticle. Int J Pharmaceutics. 1997;149:43-49.
28. Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials. 2000;21:1659-1668.
29. Shen ZH, Reznikoff G, Dranoff G, et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 1997;158:2723-2730.
30. Desai MP, Labhasetwar V, Walter E, et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1997;14:1568-1573.
31. Manzel L, Macfarlane DE. Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide. Antisense Nucleic Acid Drug Dev. 1999;9:459-464.
32. Warren TL, Bhatia SK, Acosta AM, et al. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol. 2000;165:6244-6251.
33. Singh M, Ott G, Kazzaz J, et al. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res. 2001;18:1476-1479.
34. Gursel M, Tunca S, Ozkan M, et al. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine. 1999;17:1376-1383.
35. Xie H, Gursel I, Ivins BE, et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immunity. 2005;73:828-833.
36. Kerkmann M, Costa LT, Richter C, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferonalpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem. 2005;280:8086-8093.
37. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769-776.
38. Adams A, Navabi H, Croston D, et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine. 2005;23:2374-2378.
39. Matsumoto M, Funami K, Tanabe M, et al. Subcellular localization of toll-like receptor 3 in human dendritic cells. J Immunol. 2003;171:3154-3162.
40. Weiner GJ, Woodridge JE, Liu H, et al. Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotype antibody and is synergistic with GMCSF. Blood. 1996;88:348.